<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="author" content="Andy Vo">
    <title>Renal Pharmacology</title>

    <link rel="stylesheet" href="renal_styles_4.css">
</head>

<body>
    <h1>Renal Pharmacology</h1>
    <hr>
    <p>In this section, we will be discussing diuretics, its mechanism of action (MOA); the clinical indications, contraindications, and considerations; and side effects.</p>
    <center><img src="img/diuretics_FirstAid_2020_p607.png" alt="diurectics site of action" style="max-width: calc(min(75%, 800px));"></center>

    <h2>Basic Pharmacology</h2>
    <hr>
    <h3>Osmotic diuretic</h3>
    <i>Generic</i>: Mannitol<br>
    <i>Brand names</i>:
    <table class="pharm">
        <tr id="first-row">
            <td>MECHANISM OF ACTION</td>
            <td>&uarr; tubular fluid osmolarity &rArr; &uarr; urine flow, &darr; ICP/IOP</td>
        </tr>
        <tr>
            <td>INDICATION</td>
            <td>drug O/D, &uarr; ICP/IOP</td>
        </tr>
        <tr>
            <td>CONTRAINDICATION</td>
            <td>anuria, HF</td>
        </tr>
        <tr>
            <td>ADVERSE EFFECTS</td>
            <td>Pulmonary edema, dehydration, hypo- or hypernatremia</td>
        </tr>
        <tr>
            <td>NOTES</td>
            <td>Fast-acting method of reducing ICP</td>
        </tr>
    </table>
    
    <h3>Carbonic anhydrase inhibitor</h3>
    <i>Generic</i>: Acetazolamide<br>
    <i>Brand names</i>:
    <table class="pharm">
        <tr id="first-row">
            <td>MECHANISM OF ACTION</td>
            <td>Causes self-limited sodium bicarb, diuresis, and decrease body bicar stores.<br>Alkalinizes urine</td>
        </tr>
        <tr>
            <td>INDICATION</td>
            <td>Glaucoma, metabolic alkalosis, altitude sickness, idiopathic intracranial HTN</td>
        </tr>
        <tr>
            <td>CONTRAINDICATION</td>
            <td>sulfa allergy</td>
        </tr>
        <tr>
            <td>ADVERSE EFFECTS</td>
            <td>Proximal renal tubular acidosis, parethesias, urea toxicity, hypokalemia<br>
            Promotes calcium phosphate stone formation</td>
        </tr>
        <tr>
            <td>NOTES</td>
            <td></td>
        </tr>
    </table>

    <h3>Loop diuretics</h3>
    <i>Generic</i>: furosemide, bumetanide, torsemide (sulfonamide); ethacrynic acid (non-sulfa)<br>
    <i>Brand names</i>: Lasix
    <table class="pharm">
        <tr id="first-row">
            <td>MECHANISM OF ACTION</td>
            <td>inhibits NKCC in TAL<br>prevents concentration of urine<br>&uarr; Ca<sup>2+</sup> excretion</td>
        </tr>
        <tr>
            <td>INDICATION</td>
            <td>edematous states (HF, nephrotic syndrome, pulmonary edema)<br>HTN, hypercalcemia</td>
        </tr>
        <tr>
            <td>CONTRAINDICATION</td>
            <td>sulfa allergy</td>
        </tr>
        <tr>
            <td>ADVERSE EFFECTS</td>
            <td>ototoxicity, hypokalemia, hypomagnesemia, dehydration, metabolic alkalosis, interstitial nephritis, gout</td>
        </tr>
        <tr>
            <td>NOTES</td>
            <td></td>
        </tr>
    </table>

    <h3>Thiazide diuretics</h3>
    <i>Generic</i>: hydrochlorothiazide (HCTZ), chlorthalidone, metolazone<br>
    <i>Brand names</i>:
    <table class="pharm">
        <tr id="first-row">
            <td>MECHANISM OF ACTION</td>
            <td>Inhibits NaCl co-transporter in DCT<br>&darr; Ca<sup>2+</sup> excretion</td>
        </tr>
        <tr>
            <td>INDICATION</td>
            <td>HTN, HF, idiopathic hypercalciuria, nephrogenic diabetes insipidus, osteoporosis</td>
        </tr>
        <tr>
            <td>CONTRAINDICATION</td>
            <td>sulfa allergy</td>
        </tr>
        <tr>
            <td>ADVERSE EFFECTS</td>
            <td>hypokalemic metabolic alkalosis, hyponatremia, hyperglycemia, hyperlipidemia, hyperuricemia, hypercalcemia</td>
        </tr>
        <tr>
            <td>NOTES</td>
            <td></td>
        </tr>
    </table>

    <h3>Potassium-sparing diuretics</h3>
    <i>Generic</i>: spironolactone, eplerenone, amiloride, triamterine<br>
    <i>Brand names</i>:
    <table class="pharm">
        <tr id="first-row">
            <td>MECHANISM OF ACTION</td>
            <td>-one: competitive aldosterone receptor antagonist<br>
            other 2: block ENaC</td>
        </tr>
        <tr>
            <td>INDICATION</td>
            <td>hyperaldosteronism, K<sup>+</sup> depletion, HF, hepatic ascites (spironolactone), nephrogenic DI (amiloride), antiandrogen</td>
        </tr>
        <tr>
            <td>CONTRAINDICATION</td>
            <td></td>
        </tr>
        <tr>
            <td>ADVERSE EFFECTS</td>
            <td>hyperkalemia (can lead to arrhythmias), endocrine effect with spironolactone (eg, gynocomastia, antiandrogen fx)</td>
        </tr>
        <tr>
            <td>NOTES</td>
            <td></td>
        </tr>
    </table>

    <h3>Aliskiren</h3>
    <i>Brand names</i>:
    <table class="pharm">
        <tr id="first-row">
            <td>MECHANISM OF ACTION</td>
            <td>direct renin inhibitor</td>
        </tr>
        <tr>
            <td>INDICATION</td>
            <td>HTN</td>
        </tr>
        <tr>
            <td>CONTRAINDICATION</td>
            <td>ACEi or ARBs usage (relative)<br>
            pregnancy (absolute)</td>
        </tr>
        <tr>
            <td>ADVERSE EFFECTS</td>
            <td>hyperkalemia, decrease GFR, hypotension, angioedema</td>
        </tr>
        <tr>
            <td>NOTES</td>
            <td></td>
        </tr>
    </table>

    <h2>Clinical Scenarios</h2>
    <hr>
    <p></p>

</body>